ReviewBiomolecules2026
Coagulation Assessment and Fibrinogen Thresholds in Therapeutic Plasma Exchange-A Narrative Review.
Review in Biomolecules, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Many therapeutic apheresis procedures that remove plasma or plasma components also lower coagulation factor levels, which can increase patients' bleeding risk. In this narrative review, we sum up data on clotting factor removal and the development of dilutional coagulopathy mostly associated with therapeutic plasma exchange (TPE) treatment and consider available tests for coagulation assessment. It is common in clinical practice to check fibrinogen levels regularly during repetitive TPE treatments and use it as a marker of hemostasis because of its long half-life and central role in hemostasis. We discuss the background of current clinical practice regarding fibrinogen thresholds discuss different threshold levels and data on the associated risk of bleeding. We stress the importance of additional bleeding risk assessment when patients are exposed to concomitant invasive procedures. We also describe the possibilities for fibrinogen replacement during TPE treatments with either fresh frozen plasma or fibrinogen concentrate and the associated effect on factor XIII levels. Finally, we briefly discuss alternative apheresis procedures regarding their fibrinogen-sparing potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.